SLC5A2 and type 2 diabetes mellitus: Alternatively, a meta-analysis of 247 T2DM patients from three independent trials reported that SGLT2 inhibitor treatment did not show any benefit for diabetes-induced cardiovascular autonomic dysfunction [266].